MIGUEL MACAOAY: Open Payments
NPI 1770673048 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$545 in 26 payments from 9 companies in 2025. Trend: 2023 $430 · 2024 $800 · 2025 $545
Food & beverage: $545
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $133 |
| ABBVIE INC. | 5 | $122 |
| Tris Pharma Inc | 6 | $94 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Corium, LLC | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| SANOFI PASTEUR INC. | 1 | $17 |
Products named: INGREZZA, VRAYLAR, Dyanavel XR, HETLIOZ, Onyda XR, Azstarys, Qelbree, AUSTEDO XR.
Industry payments across DC — which companies pay providers there.
